arrow
O

Omar A. Almohammed

department of clinical pharmacy
H指数:17
被引数:1,026

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative change in HbA1c and weight outcomes between obese and non-obese adults with type 2 diabetes mellitus treated with SGLT-2 inhibitors or GLP-1 receptor agonists

比较接受SGLT-2抑制剂或GLP-1受体激动剂治疗的肥胖与非肥胖2型糖尿病成人患者HbA1c和体重结局的差异性变化

2026-08-310
OA
Knowledge, attitudes, and practices of Saudi physicians toward the use of SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus: a nationwide cross-sectional study

沙特医师对2型糖尿病 mellitus患者使用SGLT-2抑制剂和GLP-1受体激动剂的知识、态度和实践:一项全国性横断面研究

2026-08-280
OAAI
Precipitating Factors, Complications, and Outcomes of Diabetic Ketoacidosis (DKA) in Adults and Pediatrics: A Descriptive Study from Two Tertiary Centers in Riyadh, Saudi Arabia

糖尿病酮症酸中毒(DKA)在成人和儿科患者中的诱发因素、并发症及结局:来自沙特阿拉伯利雅得两家三级医疗中心的描述性研究

2026-03-040
OAAI
Creating A Multi-Criteria Decision Analysis Tool to Enhance Value-Based Purchasing of Generic and Biosimilar Medications in Saudi Arabia: A Pilot Study

开发多准则决策分析工具以增强沙特阿拉伯仿制药和生物类似药的基于价值的采购:一项试点研究

2026-01-010
OAAI
Paracetamol exposure induces rapid alterations in the human plasma proteome

对乙酰氨基酚暴露诱导人类血浆蛋白质组发生快速改变

2025-08-090
PRE
Evaluating the risk of acute kidney injury and mortality associated with concomitant use of vancomycin with piperacillin/tazobactam or meropenem in critically ill and non-critically ill patients: a systematic review and meta-analysis

评估危重病和非危重病患者合并使用万古霉素与哌拉西林/他唑巴坦或美罗培南的急性肾损伤和死亡风险: 系统评价和meta分析

2025-01-070
OAAI